Portage Biotech Past Earnings Performance
Past criteria checks 0/6
Portage Biotech's earnings have been declining at an average annual rate of -59.6%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-59.6%
Earnings growth rate
-50.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -3,929.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Portage Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -71 | 6 | 10 |
| 31 Mar 24 | 0 | -75 | 6 | 13 |
| 31 Dec 23 | 0 | -145 | 6 | 13 |
| 30 Sep 23 | 0 | -113 | 6 | 13 |
| 30 Jun 23 | 0 | -109 | 6 | 10 |
| 31 Mar 23 | 0 | -105 | 7 | 9 |
| 31 Dec 22 | 0 | -17 | 8 | 8 |
| 30 Sep 22 | 0 | -14 | 9 | 7 |
| 30 Jun 22 | 0 | -16 | 9 | 7 |
| 31 Mar 22 | 0 | -17 | 9 | 7 |
| 31 Dec 21 | 0 | -21 | 10 | 10 |
| 30 Sep 21 | 0 | -19 | 8 | 8 |
| 30 Jun 21 | 0 | -18 | 6 | 8 |
| 31 Mar 21 | 0 | -16 | 5 | 7 |
| 31 Dec 20 | 0 | -6 | 2 | 3 |
| 30 Sep 20 | 0 | -6 | 2 | 4 |
| 30 Jun 20 | 0 | -5 | 2 | 4 |
| 31 Mar 20 | 0 | -5 | 2 | 4 |
| 31 Dec 19 | 0 | -6 | 2 | 5 |
| 30 Sep 19 | 0 | -5 | 2 | 4 |
| 30 Jun 19 | 0 | -4 | 1 | 3 |
| 31 Mar 19 | 0 | -3 | 1 | 2 |
| 31 Dec 18 | 0 | 124 | 1 | 0 |
| 30 Sep 18 | 0 | 124 | 1 | 0 |
| 30 Jun 18 | 0 | 124 | 1 | 0 |
| 31 Mar 18 | 0 | 124 | 1 | 1 |
| 31 Dec 17 | 0 | -10 | 1 | 29 |
| 30 Sep 17 | 0 | -16 | 1 | 29 |
| 30 Jun 17 | 0 | 19 | 1 | 29 |
| 31 Mar 17 | 0 | 16 | 3 | 32 |
| 31 Dec 16 | 0 | 24 | 2 | 5 |
| 30 Sep 16 | 0 | 27 | 6 | 7 |
| 30 Jun 16 | 0 | -8 | 6 | 8 |
| 31 Mar 16 | 0 | -6 | 5 | 5 |
| 31 Dec 15 | 0 | -6 | 5 | 4 |
| 30 Sep 15 | 0 | -3 | 1 | 3 |
| 30 Jun 15 | 0 | -3 | 1 | 3 |
| 31 Mar 15 | 0 | -3 | 1 | 3 |
| 31 Dec 14 | 0 | -4 | 2 | 3 |
| 30 Sep 14 | 0 | -3 | 2 | 2 |
| 30 Jun 14 | 0 | -3 | 2 | 2 |
Quality Earnings: PRTG is currently unprofitable.
Growing Profit Margin: PRTG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRTG is unprofitable, and losses have increased over the past 5 years at a rate of 59.6% per year.
Accelerating Growth: Unable to compare PRTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PRTG has a negative Return on Equity (-3929.28%), as it is currently unprofitable.